.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Targeted Therapies in Advanced NSCLC

EP. 1: Therapeutic Classes in Advanced NSCLC

January 13th 2016

EP. 2: Current Practices in NSCLC Genetic Testing

January 13th 2016

EP. 3: EGFR Inhibition and Resistance Mechanisms

January 13th 2016

EP. 4: Crizotinib for ALK-Rearranged NSCLC

January 13th 2016

EP. 5: Ceritinib in Crizotinib-Resistant NSCLC

January 13th 2016

EP. 6: Next-Generation ALK Inhibitors for NSCLC

January 13th 2016

EP. 7: Approval of Third-Generation TKIs for EGFR-Targeted Therapies

January 13th 2016

EP. 8: Subtypes in NSCLC: BRAF and RET

January 13th 2016

EP. 9: Emerging Targets in NSCLC Treatment

January 13th 2016